Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR

Journal of Neuroimmunology

Volumn 111, Issue 1-2, 2000, Pages 152-160

  Poussin, Mathilde A ^a   Goluszko, Elzbieta ^a   Hughes, Thomas K ^a   Duchicella, Sacha I ^a   Christadoss, Premkumar ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Autoimmunity; IL 10; IL 10 gene knockout; Immunomodulation; Myasthenia gravis

Indexed keywords

CD19 ANTIGEN; CD5 ANTIGEN; CHOLINERGIC RECEPTOR; INTERLEUKIN 10;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GENE DISRUPTION; IMMUNIZATION; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADJUVANTS, IMMUNOLOGIC; ANIMAL; ANTIGENS, CD19; ANTIGENS, CD5; AUTOANTIBODIES; B-LYMPHOCYTES; BLOOD PROTEINS; CELL DIVISION; CELL LINE; CYTOTOXINS; EPITOPES; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNIZATION; IMMUNODOMINANT EPITOPES; IN VITRO; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-6; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SKELETAL; MYASTHENIA GRAVIS, EXPERIMENTAL AUTOIMMUNE; RECEPTORS, CHOLINERGIC; SUPPORT, NON-U.S. GOV'T; TUMOR NECROSIS FACTOR;

EID: 0034333062     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00385-4     Document Type: Article

References (54)

1. Role of resident peritoneal macrophages and mast cells in chemokine production and neutrophil migration in acute inflammation: evidence for an inhibitory loop involving endogenous IL-10
2. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors
3. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10
4. Mechanism of enhanced susceptibility to sepsis following hemorrhage. Interleukin-10 suppression of T-cell response is mediated by eicosanoid-induced interleukin-4 release
5. IL-10 suppresses experimental autoimmune neuritis and down-regulates TH1-type immune responses
6. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice
7. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis
8. Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures
9. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice
10. Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3
11. B-cell-derived IL-10: production and function
12. Interleukin-10 differentially modulates MHC class II expression by mesangial cells and macrophages in vitro and in vivo
13. Immunogenetics of experimental autoimmune myasthenia gravis
14. Immunotherapy for myasthenia gravis: a murine model
15. Animal models of myasthenia gravis
16. The effect of B cell deficiency on the immune response to acetylcholine receptor and the development of experimental autoimmune myasthenia gravis
17. IFN-alpha therapy is effective in suppressing the clinical experimental myasthenia gravis
18. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function
19. Effect of myasthenic patients' immunoglobulin on acetylcholine receptor turnover: selectivity of degradation process
20. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations
21. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors
22. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells
23. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells
24. Modulation of acetylcholine receptor by antibody against the receptor
25. Precursor B cells for autoantibody production in genomically Fas-intact autoimmune disease are not subject to Fas-mediated immune elimination
26. Markers in the promoter region of interleukin-10 (IL-10) gene in myasthenia gravis: implications of diverse effects of IL-10 in the pathogenesis of the disease
27. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1
28. The role of IL-10 in human B cell activation, proliferation, and differentiation
29. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation
30. Interleukin-4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of CD4+ epitope sequences of the acetylcholine receptor
31. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis
32. Involvement of both major histocompatibility complex class II alpha and beta chains in CD4 function indicates a role for ordered oligomerization in T cell activation
33. Interleukin-10-deficient mice develop chronic enterocolitis [see comments]
34. Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens
35. Experimental autoimmune myasthenia gravis induction in B cell-deficient mice
36. Production and assay of antibodies to acetylcholine receptors
37. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus
38. Mucosal tolerance to experimental autoimmune myasthenia gravis is associated with down-regulation of AChR-specific IFN-gamma-expressing Th1-like cells and up-regulation of TGF-beta mRNA in mononuclear cells
39. Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer
40. Tumor necrosis factor-alpha, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis
41. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease
42. Cellular mechanisms of target antigen attack in experimental autoimmune myasthenia gravis
43. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats
44. IFN-alpha treatment suppresses the development of experimental autoimmune myasthenia gravis
45. Cellular mRNA expression of interferon-gamma (IFN-gamma), IL-4 and IL-10 relates to resistance to experimental autoimmune myasthenia gravis (EAMG) in young Lewis rats
46. IL-10 selectively regulates murine Ig isotype switching
47. Interleukin-12 enhances clinical experimental myasthenia gravis in susceptible but not resistant mice
48. IL-12 directly stimulates expression of IL-10 by CD5+ B cells and IL-6 by both CD5+ and CD5- B cells: possible involvement in age-associated cytokine dysregulation
49. Interleukin-12 and -10 and gamma interferon regulate polyclonal and ligand-specific expansion of murine B-1 cells
50. Experimental autoimmune myasthenia gravis in the mouse
51. Acetylcholine receptor-reactive T cells in myasthenia gravis: evidence for the involvement of different subpopulations of T helper cells
52. Both CD4+ and CD8+ T cells are essential to induce experimental autoimmune myasthenia gravis
53. Linomide suppresses both Th1 and Th2 cytokines in experimental autoimmune myasthenia gravis
54. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis